Research Use Recombinant Protein Market Projected to Reach $1.55 Billion by 2031, Driven by Expanding Drug Discovery Pipelines
Key Insights
The global research use recombinant protein market is forecast to grow from USD 1.11 billion in 2026 to USD 1.55 billion by 2031, at a CAGR of 7.0%.
North America held the largest market share at 43.6% in 2025, supported by strong pharmaceutical R&D and advanced life science infrastructure.
Cytokines and chemokines dominated the product segment with a 25.9% share in 2025, driven by extensive use in immunology and cell research.
The global research use recombinant protein market is on a steady growth trajectory, with projections indicating an increase from USD 1.11 billion in 2026 to USD 1.55 billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.0%, according to a new report from MarketsandMarkets. The market was valued at USD 1.04 billion in 2025.
The expansion is fueled by pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic research institutes increasingly incorporating recombinant proteins into drug discovery, cell culture, immunology, cancer biology, stem cell research, and disease modeling workflows. Recombinant cytokines, growth factors, chemokines, enzymes, receptors, antigens, and hormones are widely applied in cell proliferation, differentiation, signaling studies, target validation, protein interaction analysis, and assay development.
North America Leads Global Market
North America accounted for the largest share of the research use recombinant protein market in 2025, holding 43.6% of global revenue. The region's leadership is underpinned by strong pharmaceutical and biotechnology R&D activity, substantial funding for biomedical research, and widespread use of recombinant proteins in drug discovery, cell culture, immunology, cancer biology, and translational studies.
The presence of major market participants, including Thermo Fisher Scientific Inc. (search), Bio-Techne (search), and Danaher Corporation (search), further strengthens the regional ecosystem. North America also benefits from advanced research infrastructure, a large concentration of academic institutes and CROs, and early adoption of animal-free, low-endotoxin, and highly bioactive recombinant proteins across complex experimental workflows. The United States alone accounted for the largest country-level share, supported by leadership in immunology, oncology, stem cell research, neuroscience, and infectious disease studies.
Cytokines and Chemokines Dominate Product Segments
By product type, cytokines and chemokines accounted for the largest share of the market in 2025, commanding 25.9% of total revenue. Their leading position is driven by extensive use in immune-cell culture, inflammation studies, cancer research, stem cell differentiation, cell signaling, and assay development. These proteins are essential for regulating cellular proliferation, migration, activation, and differentiation across a wide range of in vitro research models.
The recurring requirement for interleukins, interferons, colony-stimulating factors, and chemotactic proteins across pharmaceutical, biotechnology, CRO, and academic laboratories supports sustained demand. Their expanding use in organoid research, immuno-oncology, infectious disease studies, and translational research further reinforces the segment's leading market position.
Mammalian Expression Systems Hold Largest Host Cell Share
By host cell, mammalian cells held the largest share of the market in 2025, owing to their ability to produce complex proteins with appropriate folding, glycosylation, disulfide bonding, and other post-translational modifications required for biological activity. Mammalian expression systems are widely used to manufacture cytokines, growth factors, receptors, ligands, antibodies, and other structurally complex proteins for cell-based assays and functional studies. Their compatibility with human and other eukaryotic proteins makes them particularly suitable for translational research, drug screening, and disease modeling.
Application and End-User Landscape
Cell culture and differentiation led the application segment with a 29.5% share in 2025, supported by widespread use of recombinant proteins in cell growth and functional studies. Pharmaceutical and biotechnology companies accounted for the largest end-user share in 2025, fueled by increasing R&D investments and expanding drug discovery pipelines.
Competitive Landscape
Thermo Fisher Scientific Inc. (search) (US), Bio-Techne (search) (US), and Merck KGaA (Germany) emerged as the leading market players based on their strong market presence and product portfolios. Other notable players include Danaher Corporation (search) (US), Revvity (US), BPS Bioscience, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sartorius AG (search) (Germany), Sino Biological, Inc. (search) (China), and GenScript (search) (China).
Among startups and SMEs, STEMCELL Technologies (Canada), RayBiotech, Inc. (US), ProSpec-Tany TechnoGene Ltd. (Israel), ProteoGenix (France), and Aviva Systems Biology Corporation (US) stood out with strong positions in specialized recombinant protein applications.
Future Opportunities
The market offers significant opportunities beyond conventional laboratory applications, particularly in organoid development, precision medicine, antibody discovery, vaccine research, and advanced disease modeling. Rising demand for high-purity, biologically active, low-endotoxin, and species-specific proteins in translational research, organoid development, biomarker discovery, and preclinical studies is accelerating market adoption. The increasing preference for animal-free, carrier-free, and GMP-compatible research proteins is supporting sensitive and reproducible experimental workflows. Ongoing advances in expression technologies, protein purification, lyophilization, quality control, and bioactivity testing are improving stability, lot-to-lot consistency, and experimental reliability, thereby supporting broader market expansion.